ZBTB46 and prostate carcinoma: We measured ZBTB46 and NGF expressions in a panel of prostate cancer cell lines, and we found that AR-negative PC326 cells and NEPC-like NCI-H6605 cells had higher ZBTB46 and NGF expressions and were positively associated with neuroendocrine marker expressions compared to AR-positive 22Rv1, LNCaP, and C4-2 cells (Fig. 1c).